Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma.
about
Better therapeutic trials in ovarian cancer.Real-world data in the molecular era-finding the reality in the real world.Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma.A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histologySurvival in women with grade 1 serous ovarian carcinomaThe anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancerOvarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problemsThe insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.Overexpression of CUEDC2 Predicts Poor Prognosis in Ovarian Serous Carcinomas.Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor.A Systems Biology Comparison of Ovarian Cancers Implicates Putative Somatic Driver Mutations through Protein-Protein Interaction Models.Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics.Prognostic significance of the mitochondrial scoring system in ovarian cancer.MET/HGF Signaling Pathway in Ovarian Carcinoma: Clinical Implications and Future Direction.Cytologic changes of ovarian epithelial cancer induced by neoadjuvant chemotherapyCritical molecular abnormalities in high-grade serous carcinoma of the ovary.Clinical implications of using molecular diagnostics for ovarian cancers.Agreement for tumor grade of ovarian carcinoma: analysis of archival tissues from the surveillance, epidemiology, and end results residual tissue repository.Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study.Key features of extrauterine pelvic serous tumours (fallopian tube, ovary, and peritoneum).Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates.The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors.Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry.Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.Early stage primary ovarian mucinous carcinoma: Outcome-based clinicopathological study in comparison with serous carcinoma.Low-grade serous carcinoma: molecular features and contemporary treatment strategies.High-grade serous carcinoma of tubo-ovarian origin: recent developments.Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer.Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma.Validation of a two-tier grading system in an unselected, consecutive cohort of serous ovarian cancer patients.Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary.Low-grade serous carcinoma of the ovary or peritoneum.Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary.[Grading of gynecological tumors : Current aspects].
P2860
Q27691432-7C7B916D-AA9E-4E06-8870-332896AEE891Q31023009-23FDAC52-43CD-4BC9-AB1F-642395FC1576Q33580777-07F8B8B1-F150-48CE-AFE3-C35C4F30F16FQ34387999-52C4875C-B1E8-4512-BEB2-AC63CEEAAFDDQ34967339-3E00BF62-7CE0-4B9C-8581-570E642C1E0AQ34984679-5998C3FE-F500-41A9-AC33-33877991D801Q34998994-EFF256A5-F2FB-4B02-8F62-02FCED8AA2D4Q35209365-8C2E0976-A085-4A00-B559-A8CE7313BFB2Q35510378-30A02EE4-F4D8-4D69-8DCA-EC4866A2EE8CQ35631627-E6FD6641-9871-4FCC-A2D7-73C38EE65EF1Q35947034-B69C00D1-5EBB-49ED-9D8B-F0BF5CFE6B21Q36176058-EA7C8A72-3B09-4E1F-BAED-79889A8F38AAQ36199823-BC089DD0-DB7B-4490-80AC-C8662AA06576Q36244076-6A683C53-77BA-4C6E-ADB6-C4498B6D8C6EQ36520263-BA93B53A-CC07-43FA-8487-50694CAC8219Q37228849-E900649F-F330-4DDB-BCF7-E4A1C3043DFAQ37232123-8BFD5106-5B8B-4D36-AB20-331FCC50FDE0Q37332490-77AD8BDE-E0B2-40AD-8A75-E4F9250D67DDQ37725019-32376E73-5FE7-40A8-9115-9B2B998D782AQ37954582-438B211D-0C59-402A-9EED-74C95B103397Q37988903-EE3268A9-C2F5-4276-AD66-7E2FE01DA638Q38067436-B9D3E369-97CA-4172-A2D6-37512B21CEE6Q38096241-AE847E18-7C08-460D-8C10-A4E3AE309CD9Q38170493-0A10DD84-3030-4A52-885D-23C9BCF14BC2Q38372474-8E975E78-4B50-4DF0-BE41-8CF4957AB0A8Q38382139-46B02D14-96BD-47DD-9486-E9131E865DBAQ38514737-D42153ED-1259-49EF-B096-CA191F49D55DQ38687061-911A35EF-8E55-429E-BFEE-C23ACFE1FC9EQ40344519-5C692A28-D9D0-4FD6-9F18-7E024BC14F67Q40602149-724CE046-A684-4BD3-B629-6324BA977287Q40844578-0C093876-BE9F-4B60-8094-ED73803F62ECQ47136918-A9D0367D-9D8C-4343-95E5-B7B3A1D51372Q50856533-F0BA9568-B2F0-4928-8B8F-7C065E4BED1AQ51609396-284E91B8-D5BF-4045-9138-54A2715E3F31Q52861155-73577FDA-7B14-45FE-AF27-B96286093E9D
P2860
Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Interobserver and intraobserve ...... ding ovarian serous carcinoma.
@en
type
label
Interobserver and intraobserve ...... ding ovarian serous carcinoma.
@en
prefLabel
Interobserver and intraobserve ...... ding ovarian serous carcinoma.
@en
P2093
P1476
Interobserver and intraobserve ...... ding ovarian serous carcinoma.
@en
P2093
Carmen Tornos
David Frishberg
Elvio G Silva
Erich Gaertner
Jeffrey D Seidman
Mark F Munsell
Michael T Deavers
Robert J Kurman
Robert Soslow
P304
P356
10.1097/PAS.0B013E31803199B0
P407
P577
2007-08-01T00:00:00Z